跳至主要内容
临床试验/JPRN-UMIN000043659
JPRN-UMIN000043659招募中未知

Quizartinib cohort study bridging to hematopoietic stem cell transplantation in patients with FLT3-ITD positive acute myeloid leukemia; QUICHE study. - KSGCT2101(Quiche)

Kanto Study Group for Cell Therapy0 个研究点目标入组 40 人开始时间: 2021年4月1日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 70years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Patients treated with quizartinib 2) Patients with multiple malignancies other than AML 3) Patients diagnosed with acute promyelocytic leukemia 4) Patients with a QTcF (Fridericia-corrected QT interval) greater than 450 msec as a result of the latest electrocardiogram measured within 14 days prior to enrollment 5) Patients known to have HIV or HBV 6) Patients who have already achieved remission with treatment other than quizartinib at the stage of disease ("primary" or "relapsed or refractory") at the time of enrollment and are scheduled to receive allo-HSCT. 7) Pregnant or lactating patients, or patients who may be breastfeeding within 5 weeks of the last dose of quizartinib 8) Patients who are otherwise classified as unfit by the attending physicians for this research.

研究者

发起方
Kanto Study Group for Cell Therapy

相似试验